Alvotech announces webcast of first quarter 2024 financial results

REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotechnology company focused on the development and manufacturing of biosimilar medicines for patients around the world, today announced that it will release its financial results for the first quarter. closed on March 31, 2024, after the close of the US markets on Tuesday, May 21, 2024.

Alvotech will also host a conference call with analysts to present first quarter 2024 financial results and business highlights on Wednesday, May 22, 2024, at 8:00 a.m. EDT (12:00 GMT). Live audio of the conference call will be webcast and available to members of the news media, investors and the general public.

Information on how to access the webcast or participate via conference call is posted on the Alvotech investors website https://investors.alvotech.com. A direct link to the event is https://investors.alvotech.com/events/event-details/q1-2024-earnings. The webcast will also be archived and available for replay for 90 days following the event.

About Alvotech
Alvotech is a biotechnology company founded by Robert Wessman, focused solely on the development and manufacturing of biosimilar medicines for patients worldwide. Alvotech seeks to become a global leader in biosimilars by providing high-quality, cost-effective products and services, enabled by a fully integrated approach and extensive internal capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates for the treatment of autoimmune diseases, ocular disorders, osteoporosis, respiratory diseases and cancer. Alvotech has formed a network of strategic business partnerships to provide global reach and leverage local expertise in markets including the United States, Europe, Japan, China and other Asian countries and major parts from South America, Africa and the Middle East. Alvotech’s business partners include Teva Pharmaceuticals, a US subsidiary of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines and South Korea). Each business partnership covers a unique set of products and territories. Unless otherwise indicated, Alvotech disclaims all responsibility for the content of periodic documents, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website will be considered part of this press release.

ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATION
Benedikt Stefansson, senior director
[email protected]

Please visit our Investor Portal and website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube.